{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:02:31Z","timestamp":1777143751120,"version":"3.51.4"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.prp.2022.154241","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:08:19Z","timestamp":1669284499000},"page":"154241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Recent progress in cancer immunotherapy: Overview of current status and challenges"],"prefix":"10.1016","volume":"241","author":[{"given":"Mohammad","family":"Darvishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foad","family":"Tosan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooria","family":"Nakhaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danial Amiri","family":"Manjili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar Afzali","family":"Kharkouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Ilkhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farima","family":"Khalafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firoozeh Abolhasani","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed-Ghavam","family":"Shafagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12020-011-9578-7","article-title":"TGF-\u03b2 and IL-23 gene expression in unstimulated PBMCs of patients with diabetes","volume":"41","author":"Abbasi","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.prp.2022.154241_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2022.154241_bib3","unstructured":"L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge,\u00a0et al. Nature 2013 258."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib4","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib5","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/cancers12113189","article-title":"IL-2 and anti-TGF-\u03b2 promote NK cell reconstitution and anti-tumor effects after syngeneic hematopoietic stem cell transplantation","volume":"12","author":"Alvarez","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2022.154241_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","author":"Amin","year":"2014","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CJI.0000000000000286","article-title":"Anti-\u03b1FR CAR-engineered NK-92 cells display potent cytotoxicity against \u03b1FR-positive ovarian cancer","volume":"42","author":"Ao","year":"2019","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4441-3","article-title":"Mechanisms of immune evasion in breast cancer","volume":"18","author":"Bates","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"Suppl 1","key":"10.1016\/j.prp.2022.154241_bib13","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.21037\/jtd.2018.11.102","article-title":"Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors","volume":"11","author":"Berland","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cncr.32498","article-title":"Prostate cancer in young men: an emerging young adult and older adolescent challenge","volume":"126","author":"Bleyer","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378843","article-title":"Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model","volume":"7","author":"Bocca","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CMR.0b013e3283538293","article-title":"Combined vaccine+ axitinib therapy yields superior anti-tumor efficacy in a murine melanoma model","volume":"22","author":"Bose","year":"2012","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2022.154241_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.smim.2018.10.011","article-title":"Aging, inflammation and cancer","volume":"40","author":"Bottazzi","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.prp.2022.154241_bib18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib19","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1172\/JCI80012","article-title":"Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade","volume":"125","author":"Buchbinder","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2013.05.031","article-title":"Challenges in cancer vaccine development for hepatocellular carcinoma","volume":"59","author":"Buonaguro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prp.2022.154241_bib21","doi-asserted-by":"crossref","unstructured":"S. Candeias, S. Gaipl, U. The immune system in cancer prevention, development and therapy Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem. -Anti-Cancer Agents), 16, 1, 2016, pp. 101\u2013107.","DOI":"10.2174\/1871520615666150824153523"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.nano.2016.10.015","article-title":"Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma","volume":"13","author":"Cano-Mejia","year":"2017","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00262-016-1831-8","article-title":"Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer","volume":"65","author":"Cappuccini","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2589","article-title":"Factors associated with use of sipuleucel-t to treat patients with advanced prostate cancer","volume":"2","author":"Caram","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/1060028020962050","article-title":"Heplisav-B: a hepatitis B vaccine with a novel adjuvant","volume":"55","author":"Champion","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11426-018-9397-5","article-title":"Precise nanomedicine for intelligent therapy of cancer","volume":"61","author":"Chen","year":"2018","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.prp.2022.154241_bib28","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.2147\/OTT.S168313","article-title":"Drug response to PD-1\/PD-L1 blockade: based on biomarkers","volume":"11","author":"Chen","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.prp.2022.154241_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066721","article-title":"Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-7-293","article-title":"Spontaneous regression of metastatic cancer cells in the lymph node: a case report","volume":"7","author":"Choi","year":"2014","journal-title":"BMC Res. Notes"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nano.2014.09.009","article-title":"Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab","volume":"11","author":"Choi","year":"2015","journal-title":"Nanomed.: Nanotechnol., Biol. Med."},{"key":"10.1016\/j.prp.2022.154241_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4504","article-title":"First-line avelumab+ axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial","author":"Choueiri","year":"2017","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2022.154241_bib35","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.prp.2022.154241_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","author":"Coillie","year":"2020","journal-title":"Regul. Cancer Immune Checkp."},{"issue":"12","key":"10.1016\/j.prp.2022.154241_bib37","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","article-title":"PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients.","volume":"6","author":"Concha-Benavente","year":"2018","journal-title":"Cancer Immunol. Res"},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.prp.2022.154241_bib39","doi-asserted-by":"crossref","unstructured":"Couzin-Frankel J., Cancer immunotherapy. American Association for the Advancement of Science, (2013).","DOI":"10.1126\/science.342.6165.1432"},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/neuonc\/noz117","article-title":"Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma","volume":"21","author":"Cui","year":"2019","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"34","key":"10.1016\/j.prp.2022.154241_bib42","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody Pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"24","key":"10.1016\/j.prp.2022.154241_bib44","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"de Lara","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2022.154241_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2018.09.026","article-title":"The application of nanotechnology in immune checkpoint blockade for cancer treatment","volume":"290","author":"Deng","year":"2018","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","article-title":"Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors","volume":"65","author":"Derer","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib48","first-page":"351","article-title":"Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs","volume":"18","author":"Dranitsaris","year":"2018","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM\u2010CSF\u2010based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol. Rev."},{"issue":"30","key":"10.1016\/j.prp.2022.154241_bib50","doi-asserted-by":"crossref","first-page":"E6157","DOI":"10.1073\/pnas.1700363114","article-title":"Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas","volume":"114","author":"Du","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.prp.2022.154241_bib51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","article-title":"Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients","volume":"65","author":"Duffy","year":"2019","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib52","first-page":"747","article-title":"Immunotherapy through the years","volume":"8","author":"Eno","year":"2017","journal-title":"J. Adv. Pract. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","article-title":"Cyclophosphamide and vinorelbine activate stem-like CD8(+) T cells and improve Anti-PD-1 efficacy in triple-negative breast cancer","volume":"81","author":"Falvo","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib54","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","article-title":"Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer","volume":"81","author":"Falvo","year":"2021","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.prp.2022.154241_bib55","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.7150\/thno.29035","article-title":"Adoptive cell transfer: is it a promising immunotherapy for colorectal cancer?","volume":"8","author":"Fan","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2022.154241_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12020-019-01859-3","article-title":"Association and gene\u2013gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease","volume":"64","author":"Fathima","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.prp.2022.154241_bib58","first-page":"321","article-title":"The unusual paradox of cancer-associated inflammation: an update","volume":"55","author":"Figueiredo","year":"2019","journal-title":"J. Bras. De. Patol. e Med. Lab."},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2022.154241_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib61","first-page":"473","article-title":"T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer","volume":"10","author":"Fu","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib62","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","article-title":"Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors","volume":"74","author":"Fu","year":"2014","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib63","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib64","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1158\/0008-5472.CAN-21-1237","article-title":"The dawn of myeloid-derived suppressor cells: identification of arginase I as the mechanism of immune suppression","volume":"81","author":"Gabrilovich","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.prp.2022.154241_bib65","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4161\/onci.19549","article-title":"Trial watch: adoptive cell transfer immunotherapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2022.154241_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/imr.12574","article-title":"Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses","volume":"280","author":"Garg","year":"2017","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib70","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"18","key":"10.1016\/j.prp.2022.154241_bib71","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.vaccine.2019.03.052","article-title":"Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"37","author":"Godi","year":"2019","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.prp.2022.154241_bib72","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2022.154241_bib73","first-page":"9","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","author":"Guallar-Garrido","year":"2020","journal-title":"ImmunoTargets Ther."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib74","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib75","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"7528","key":"10.1016\/j.prp.2022.154241_bib76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.prp.2022.154241_bib77","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6248590","article-title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer","volume":"2018","author":"Han","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib78","article-title":"Advances in combination therapy of immune checkpoint inhibitors for lung cancer","volume":"23","author":"Hanfei","year":"2020","journal-title":"Chin. J. Lung Cancer"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib79","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib80","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrd3162","article-title":"Calming the cytokine storm","volume":"9","author":"Harrison","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib81","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib82","first-page":"2561","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc\u03b3RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib83","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"7528","key":"10.1016\/j.prp.2022.154241_bib85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib86","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2022.154241_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib89","first-page":"2444","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib90","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti\u2013CTLA-4 therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.prp.2022.154241_bib91","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.154241_bib93","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"issue":"6382","key":"10.1016\/j.prp.2022.154241_bib94","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib95","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/vaccines8020317","article-title":"PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer","volume":"8","author":"Kadam","year":"2020","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib96","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2326-6066.CIR-18-0605","article-title":"Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinomaHCC with complete response after immunotherapy","volume":"7","author":"Kaseb","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib97","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.prp.2022.154241_bib98","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.prp.2022.154241_bib99","article-title":"CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges","volume":"110","author":"Khorasani","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)71191-X","article-title":"FDA approves new upgraded Gardasil 9","volume":"16","author":"Kirby","year":"2015","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.prp.2022.154241_bib101","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/pros.22858","article-title":"Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer","volume":"74","author":"Klyushnenkova","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.prp.2022.154241_bib102","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4072","article-title":"First-line avelumab+ axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)","author":"Kudo","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib104","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.prp.2022.154241_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104957","article-title":"Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma","volume":"159","author":"Lacal","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib106","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-019-02411-y","article-title":"Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine","volume":"68","author":"Lapenta","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib107","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.prp.2022.154241_bib109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.prp.2022.154241_bib110","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/1078-0432.CCR-16-0143","article-title":"Repurposing sunitinib with oncolytic reovirus as a novel immunotherapeutic strategy for renal cell carcinoma","volume":"22","author":"Lawson","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib112","first-page":"1","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2022.154241_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib114","doi-asserted-by":"crossref","first-page":"970","DOI":"10.7150\/thno.11632","article-title":"CD44v6 monoclonal antibody-conjugated gold nanostars for targeted photoacoustic imaging and plasmonic photothermal therapy of gastric cancer stem-like cells","volume":"5","author":"Liang","year":"2015","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbcan.2018.01.005","article-title":"Reformation in chimeric antigen receptor based cancer immunotherapy: redirecting natural killer cell","volume":"1869","author":"Lin","year":"2018","journal-title":"Biochim. Et Biophys. Acta(BBA) Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib116","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/or.2020.7862","article-title":"Specific growth inhibition of ErbB2\u2013expressing human breast cancer cells by genetically modified NK\u201192 cells","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/j.prp.2022.154241_bib117","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib120","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib121","doi-asserted-by":"crossref","first-page":"912","DOI":"10.36468\/pharmaceutical-sciences.721","article-title":"Assessment of anti-proliferative effect of extract fractions of euphorbia neriifolia leaves in human prostate adenocarcinoma DU-145 cells","volume":"82","author":"Mali","year":"2020","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.prp.2022.154241_bib122","series-title":"Mayo Clinic Proceedings","first-page":"1321","article-title":"Immune checkpoint inhibitor toxicities","author":"Marin-Acevedo","year":"2019"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib124","doi-asserted-by":"crossref","DOI":"10.1111\/cas.14993","article-title":"CAR\u2010NK cell in cancer immunotherapy; a promising frontier","author":"Marofi","year":"2021","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.prp.2022.154241_bib126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib127","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2022.154241_bib130","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4054815","article-title":"Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies","volume":"2018","author":"Matosevic","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"16","key":"10.1016\/j.prp.2022.154241_bib131","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib132","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib133","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.154241_bib134","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib135","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"25","key":"10.1016\/j.prp.2022.154241_bib136","doi-asserted-by":"crossref","first-page":"1706098","DOI":"10.1002\/adma.201706098","article-title":"A dual immunotherapy nanoparticle improves T\u2010cell activation and cancer immunotherapy","volume":"30","author":"Mi","year":"2018","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.prp.2022.154241_bib138","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib139","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12721","article-title":"What did we learn from CTLA\u20104 insufficiency on the human immune system?","volume":"287","author":"Mitsuiki","year":"2019","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib141","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib142","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10787-017-0332-5","article-title":"Melatonin as an anti-inflammatory agent in radiotherapy","volume":"25","author":"Najafi","year":"2017","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib143","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.prp.2022.154241_bib144","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.prp.2022.154241_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118492","article-title":"Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study","volume":"567","author":"Nikpoor","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib147","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.154241_bib148","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J. Cancer Metastasis Treat."},{"issue":"10","key":"10.1016\/j.prp.2022.154241_bib149","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.154241_bib150","doi-asserted-by":"crossref","unstructured":"M.J. Overman, S. Lonardi, K.Y.M. Wong\u00a0et al., Durable Clin. Benefit nivolumab ipilimumab DNA mismatch Repair-deficient\/Micro Instab. -High. metastatic Colorectal Cancer, 2018.","DOI":"10.1200\/JCO.2017.76.9901"},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib151","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib152","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13237-017-0194-7","article-title":"Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation","volume":"60","author":"Panda","year":"2017","journal-title":"Nucleus"},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib153","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nm0598supp-525","article-title":"Cancer vaccines","volume":"4","author":"Pardoll","year":"1998","journal-title":"Nat. Med."},{"issue":"10212","key":"10.1016\/j.prp.2022.154241_bib154","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/107327481302000406","article-title":"Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy","volume":"20","author":"Phan","year":"2013","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib156","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.prp.2022.154241_bib157","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.07.006","article-title":"Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance","volume":"123","author":"Pulluri","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-021-00248-9","article-title":"Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort","volume":"10","author":"Rabinovich","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib159","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.prp.2022.154241_bib160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib161","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.prp.2022.154241_bib162","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.19.00345","article-title":"Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition\u2014a pooled analysis of patients with advanced melanoma","volume":"37","author":"Regan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib163","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib164","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1084\/jem.20181739","article-title":"Modulating inflammation for cancer therapy","volume":"216","author":"Ritter","year":"2019","journal-title":"J. Exp. Med."},{"issue":"6230","key":"10.1016\/j.prp.2022.154241_bib165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib166","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib168","first-page":"58","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib169","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/imt-2018-0009","article-title":"Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma","volume":"10","author":"Saha","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2022.154241_bib171","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J. Transl. Med."},{"issue":"16","key":"10.1016\/j.prp.2022.154241_bib172","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co\u2010administration of CD19\u2013and CD20\u2013targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib173","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib174","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"issue":"6230","key":"10.1016\/j.prp.2022.154241_bib175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.prp.2022.154241_bib176","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib177","doi-asserted-by":"crossref","first-page":"a005090","DOI":"10.1101\/cshperspect.a005090","article-title":"Angiogenesis","volume":"3","author":"Senger","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"13","key":"10.1016\/j.prp.2022.154241_bib178","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8(+) T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib179","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib180","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Shaw","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib181","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.gendis.2019.06.006","article-title":"Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies","volume":"6","author":"Shen","year":"2019","journal-title":"Genes Dis."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065757","article-title":"Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2022.154241_bib183","unstructured":"T.G. Shrihari, Inflamm. -Relat. Cancer Or. Cancer-Relat. Inflamm. Eur. Res. J., 4, 1, 2017, pp. 1\u20135."},{"issue":"15","key":"10.1016\/j.prp.2022.154241_bib184","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.154241_bib185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.critrevonc.2017.03.003","article-title":"Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature","volume":"113","author":"Sindoni","year":"2017","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib186","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib187","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib188","first-page":"1","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib189","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2022.154241_bib190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/OTT.S122974","article-title":"nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors","volume":"10","author":"Soliman","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2022.154241_bib191","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biomaterials.2017.09.017","article-title":"Nanomaterials for cancer immunotherapy","volume":"148","author":"Song","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib192","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy","volume":"33","author":"Stephan","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib193","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11060-020-03459-y","article-title":"Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice","volume":"147","author":"Stessin","year":"2020","journal-title":"J. neuro-Oncol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib194","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J. Recept. Signal Transduct."},{"key":"10.1016\/j.prp.2022.154241_bib195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"Pd-1\/pd-l1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib196","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/ijc.29163","article-title":"Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft","volume":"136","author":"Tan","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib197","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib198","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"7541","key":"10.1016\/j.prp.2022.154241_bib199","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130\u2013Src\u2013YAP module links inflammation to epithelial regeneration","volume":"519","author":"Taniguchi","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/07357907.2017.1351984","article-title":"Tumor infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients","volume":"35","author":"Tas","year":"2017","journal-title":"Cancer Investig."},{"key":"10.1016\/j.prp.2022.154241_bib201","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fimmu.2020.00895","article-title":"A new strategy toward B cell-based cancer vaccines by active immunization with mimotopes of immune checkpoint inhibitors","volume":"11","author":"Tobias","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.4251","article-title":"Massively\u2010parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary","volume":"231","author":"Tothill","year":"2013","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib203","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41551-018-0266-2","article-title":"Challenges towards the realization of individualized cancer vaccines","volume":"2","author":"T\u00fcreci","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.prp.2022.154241_bib204","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/cas.14374","article-title":"Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda","year":"2020","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib205","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib206","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"Van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.prp.2022.154241_bib207","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.15917","article-title":"Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model","volume":"8","author":"Vo","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib208","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2022.154241_bib209","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","article-title":"Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody","volume":"16","author":"Wang","year":"2016","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1667\/RR15182.1","article-title":"Impact of radiotherapy concurrent with anti-PD-1 therapy on the lung tissue of tumor-bearing mice","volume":"191","author":"Wang","year":"2019","journal-title":"Radiat. Res."},{"issue":"6","key":"10.1016\/j.prp.2022.154241_bib211","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1189\/jlb.5RU0817-315R","article-title":"Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy","volume":"102","author":"Wang","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib212","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells","volume":"6","author":"Wang","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2022.154241_bib213","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1158\/1940-6207.CAPR-17-0108","article-title":"PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions","volume":"10","author":"Wang","year":"2017","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.prp.2022.154241_bib214","first-page":"3","article-title":"Chimeric antigen receptor T cell therapy in cancer: advances and challenges","volume":"3","author":"Wang","year":"2021","journal-title":"Aging Pathobiol. Ther."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib215","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-020-02576-x","article-title":"Anti-angiogenesis therapy overcomes the innate resistance to PD-1\/PD-L1 blockade in VEGFA-overexpressed mouse tumor models","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib216","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41416-018-0297-1","article-title":"Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro-or macro-metastatic disease","volume":"120","author":"Wu","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib217","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","article-title":"CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma","volume":"11","author":"Wu","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.prp.2022.154241_bib218","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bulcan.2019.03.012","article-title":"HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer","volume":"106","author":"Wu","year":"2019","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.prp.2022.154241_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109458","article-title":"Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice","volume":"120","author":"Xu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.20892\/j.issn.2095-3941.2018.0493","article-title":"Current applications and future prospects of nanotechnology in cancer immunotherapy","volume":"16","author":"Yan","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.prp.2022.154241_bib221","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.prp.2022.154241_bib222","article-title":"Nanotechnology platforms for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib223","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/cei.12069","article-title":"Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR 2) induces synergistic anti\u2010tumour effect in vivo","volume":"172","author":"Yasuda","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2022.154241_bib224","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Yu","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib225","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1002\/jcp.26361","article-title":"Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy","volume":"233","author":"Zamani","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.prp.2022.154241_bib226","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2022.154241_bib227","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2022.154241_bib228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2022.154241_bib229","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anndiagpath.2019.04.004","article-title":"The predictive and prognostic value of Foxp3+\/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer","volume":"40","author":"Zhang","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"issue":"7","key":"10.1016\/j.prp.2022.154241_bib230","doi-asserted-by":"crossref","first-page":"1906922","DOI":"10.1002\/adfm.201906922","article-title":"In situ formed fibrin scaffold with cyclophosphamide to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.prp.2022.154241_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101035","article-title":"Nanotechnology enabled reactive species regulation in biosystems for boosting cancer immunotherapy","volume":"36","author":"Zhang","year":"2021","journal-title":"Nano Today"},{"issue":"13","key":"10.1016\/j.prp.2022.154241_bib232","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/imt-2020-0009","article-title":"Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects","volume":"12","author":"Zhang","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2022.154241_bib233","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.prp.2022.154241_bib234","doi-asserted-by":"crossref","first-page":"4263520","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.prp.2022.154241_bib235","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"13","key":"10.1016\/j.prp.2022.154241_bib236","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1021\/jacs.0c00992","article-title":"Employing an ICT-FRET integration platform for the real-time tracking of SO2 metabolism in cancer cells and tumor models","volume":"142","author":"Zhang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.prp.2022.154241_bib237","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fphar.2019.01184","article-title":"Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.prp.2022.154241_bib238","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/pgs-2019-0184","article-title":"Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy","volume":"21","author":"Zhao","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.prp.2022.154241_bib239","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CJI.0000000000000242","article-title":"Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model","volume":"41","author":"Zheng","year":"2018","journal-title":"J. Immunother."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200485X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200485X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:56:40Z","timestamp":1759733800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382200485X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":239,"alternative-id":["S034403382200485X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.154241","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in cancer immunotherapy: Overview of current status and challenges","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.154241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154241"}}